Onco-Innovations Reaches Critical Manufacturing Milestone as Nasdaq Ambitions and Phase 1 Trial Converge

Onco-Innovations has crossed a pivotal regulatory threshold for its lead oncology candidate, ONC010, by launching the validation of analytical methods for the active pharmaceutical ingredient. The Canadian micro-cap biotech is working with contract manufacturer Dalton Pharma Services to ensure the drug substance meets international standards for impurities and residual solvents — a prerequisite for filing an investigational new drug (IND) application. Once that IND is formally submitted, the door swings open for human clinical trials, with the company targeting the start of a Phase?1 study in Australia during 2026, where R&D tax credits can refund up to 43.5?% of eligible costs.

ONC010 is built on PNKP inhibitor technology, an approach designed to block DNA repair mechanisms in cancer cells, forcing malignant cells to die off. The validation work currently underway provides the analytical backbone that regulators demand before first-in-human testing can begin. Management has stressed that robust, validated methods are the necessary foundation for the transition into the clinic.

Alongside this preclinical push, Onco-Innovations is actively preparing a secondary listing on the Nasdaq. A US-based investment banker is coordinating the effort, which would give the company access to institutional capital and raise its profile in the global biotech arena. The groundwork was laid in February 2026 with the filing of a preliminary base prospectus in Canada, a document that, once cleared by regulators, will allow flexible capital raises to fund further clinical development.

Should investors sell immediately? Or is it worth buying Onco-Innovations?

The Nasdaq initiative complements the company’s widening alliances with big pharma. Onco-Innovations has forged partnerships with AstraZeneca and GSK centred on the PROmAI programme, which employs multimodal artificial intelligence to sharpen predictions of clinical outcomes in oncology. CEO Thomas O’Shaughnessy has described the AI work as providing the analytical precision needed to de?risk the move into Phase?1.

The stock has been see?sawing on the news flow. On Monday, shares slipped 4?% to €0.67, but they remain roughly 30?% above their 50?day moving average, a clear sign of momentum?driven buying interest. Year?to?date, the equity is still down about 21?%, and the 52?week high of €1.49 remains a distant memory. With a market capitalisation of roughly EUR?42?million and annualised volatility near 134?%, Onco-Innovations remains a high?speculation play. The next big catalysts — the IND submission, the start of the ONC010 Phase?1 trial, and progress on the Nasdaq listing — are likely to dictate the direction in the months ahead.

Ad

Onco-Innovations Stock: New Analysis - 18 May

Fresh Onco-Innovations information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Onco-Innovations analysis...

en | CA68237C1059 | ONCO-INNOVATIONS | boerse | 69366906 |